Connect
← Return to New type of test for PSA: Prostate Screening EpiSwitch (PSE) test
Discussion
New type of test for PSA: Prostate Screening EpiSwitch (PSE) test
Prostate Cancer | Last Active: Apr 15 10:15pm | Replies (26)Comment receiving replies
Jeff,
Thanks for the clarification reply. I am monitoring PSA using the Ultrasensitive test post radical prostatectomy and seeing a rise (still below 0.1). Scans have not revealed anything. Do you know if Medcare will cover any of the costs of the PSE test?
Ralph
Replies to "Jeff, Thanks for the clarification reply. I am monitoring PSA using the Ultrasensitive test post radical..."
The ultrasensitive test may actually be testing down to 0.01 rather than just 0.1. If your PSA is undetectable down to 0.01, then I can't imagine an epigenetic component adding any extra info — its main *approved* use is for reducing false positives during routine PSA screening (i.e. if you have a borderline PSA like 10, it can help determine whether it's more or less likely to be cancer related).
The makers are also pushing to have it used for surveillance of existing cancer — even there, though, I didn't think it would matter unless/until you had rising PSA. PSA is the primary indicator, and EpiSwitch is just an extra refinement to help determine how serious rising PSA is.
Connect
The FDA has approved this test so it should be covered if your doctor orders it.